(NASDAQ: HUMA) Humacyte's forecast annual revenue growth rate of 379.66% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 108.62%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.33%.
Humacyte's revenue in 2025 is $818,000.On average, 9 Wall Street analysts forecast HUMA's revenue for 2025 to be $587,402,390, with the lowest HUMA revenue forecast at $434,573,243, and the highest HUMA revenue forecast at $831,453,908. On average, 9 Wall Street analysts forecast HUMA's revenue for 2026 to be $9,211,242,326, with the lowest HUMA revenue forecast at $2,017,661,484, and the highest HUMA revenue forecast at $39,442,589,686.
In 2027, HUMA is forecast to generate $13,499,960,771 in revenue, with the lowest revenue forecast at $6,363,393,911 and the highest revenue forecast at $25,459,910,531.